A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

NCT06487858 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
42
Enrollment
INDUSTRY
Sponsor class

Stopped This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors.

Conditions

Interventions

Sponsor

BeOne Medicines